Novartis has announced that the European Commission has approved Zykadia (ceritinib) to treat adult patients with anaplastic lymphoma kinase (ALK)-positive...
The UK's National Institute for Health and Care Excellence (NICE) does not recommend Zykadia (ceritinib) from Novartis, for use in...
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive...
UK's NICE has announced that Zykadia (ceritinib), from Novartis, has been recommended in line with its marketing authorisation, for the...
The second-generation ALK tyrosine kinase inhibitor brigatinib has recently been approved in the European Union for use after crizotinib treatment in patients with EML4–ALK-rearranged lung cancer.
Areas covered: The authors review the development and characteristics of brigatinib and discuss the optimal clinical use and sequence of the application of ALK inhibitors in patients progressing under therapy.
Pfizer announced that the European Commission (EC) granted conditional marketing authorization for Lorviqua (lorlatinib, available in the U.S., Canada and...
Novartis announced new data, from ASCEND-1 study, showing patients with anaplastic lymphoma kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) lived...
Approximately 3-5% of patients with non-small cell lung cancer (NSCLC)belonged to anaplastic lymphoma kinase (ALK)-positive NSCLC. The treatment drugs of ALK-positive NSCLC mainly included crizotinib, ceritinib, alectinib, and brigatinib.
Pfizer announced that the European Commission granted marketing authorization for Lorviqua (lorlatinib) available in the U.S. under the brand name Lorbrena as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.